FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileParadigm Biopharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
PAR.AX
Paradigm Biopharmaceuticals Limited Stock AnalysisComprehensive stock analysis for Paradigm Biopharmaceuticals Limited (PAR.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPAR.AX
PAR.AX
Paradigm Biopharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
PAR.AX
  1. Home
  2. Stocks
  3. Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Limited

🇦🇺PAR.AX•ASX

Paradigm Biopharmaceuticals Limited

🇦🇺PAR.AX•ASX

Your view on PAR.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Paradigm Biopharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Paul John Rennie
Headquarters
500 Collins Street, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Paul John Rennie
Headquarters
500 Collins Street, Melbourne, VIC, AU
Description

Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health.

A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Paradigm Biopharmaceuticals Limited. Starting points for Paradigm Biopharmaceuticals Limited: EPS -AUD 0.16, beta -0.01 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Paradigm Biopharmaceuticals Limited. Paradigm Biopharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Paradigm Biopharmaceuticals Limited. Trailing twelve-month EPS for Paradigm Biopharmaceuticals Limited stands at -AUD 0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.08AUD 0.18
Lowest estimate−AUD 0.10AUD 0.07
Highest estimate−AUD 0.07AUD 0.29
Number of analysts22
A year ago−AUD 0.151—
Growth vs a year ago——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 3.26MAUD 321.90M
Lowest estimateAUD 1.25MAUD 123.50M
Highest estimateAUD 5.27MAUD 520.30M
Number of analysts22
A year agoAUD 80150.00—
Growth vs a year ago+3967.4%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Paradigm Biopharmaceuticals Limited. Paradigm Biopharmaceuticals Limited has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PAR.AX20 companies
Compare PAR.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ACW.AXActinogen Medical LimitedHealthcareBiotechnology—
AHC.AXAustco Healthcare LimitedHealthcareMedical - Instruments & Supplies—
ALA.AXArovella Therapeutics LimitedHealthcareBiotechnology—
AVH.AXAVITA Medical, Inc.HealthcareMedical - Devices—
EMV.AXEMVision Medical Devices LtdHealthcareMedical - Devices—
NYR.AXNyrada Inc.HealthcareBiotechnology—
ONE.AXOneview Healthcare PLCHealthcareMedical - Healthcare Information Services—
PEB.AXPacific Edge LimitedHealthcareMedical - Diagnostics & Research—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PALIPalisade Bio, Inc.HealthcareNASDAQ$168.9M
PANCPanacos Pharmaceuticals, Inc.HealthcareOTC$5,367
PARDPoniard Pharmaceuticals, Inc.HealthcareOTC$150
PASGPassage Bio, Inc.HealthcareNASDAQ$12.9M
PBIGFParadigm Biopharmaceuticals LimitedHealthcareOTC$87.9M
PBLAPanbela Therapeutics, Inc.HealthcareOTC$53,889
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.5B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$47,738
PBMWWPsyence Biomedical Ltd. WarrantHealthcareNASDAQ$869
PBYIPuma Biotechnology, Inc.HealthcareNASDAQ$373.3M
PCSAProcessa Pharmaceuticals, Inc.HealthcareNASDAQ$4.8M
PCVXVaxcyte, Inc.HealthcareNASDAQ$9.3B
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Paradigm Biopharmaceuticals Limited.

PAR.AX AnalysisFair
Past
1
Growth
4
Health
3
Profit
1
Value
1